of the NS3 regions of HGV and GBV-C are 85% identical and Criteria for severity of viral hepatitis were previously reported the amino acid sequences are 100% identical, suggesting that [19]. Patients were interviewed for relevant clinical and epidemiologic data. Serum samples were available from all patients on HGV and GBV-C are independent isolates of the same virus.
Despite the availability of diagnostic tests for detection of as etiologic factors [16] . However, the clinical impact of HGV infection remains to be fully elucidated. We sought to determine hepatitis C virus (HCV) [1, 2] and hepatitis E virus (HEV) [3 -5] , cases of acute and chronic hepatitis in which patients the role of HGV infection in the etiology of non-A-E hepatitis. do not exhibit markers for any known hepatitis viruses still exist [6 -8] and are referred to as non-A -E hepatitis. Some
Materials and Methods

4% -20% of acute hepatitis cases in Europe and the United
Patients. Adult viral hepatitis patients 15-75 years of age, all
States are associated with non-A -E hepatitis [9 -12] . Although tis cases are of unknown etiology [13] . of the NS3 regions of HGV and GBV-C are 85% identical and Criteria for severity of viral hepatitis were previously reported the amino acid sequences are 100% identical, suggesting that [19] . Patients were interviewed for relevant clinical and epidemiologic data. Serum samples were available from all patients on HGV and GBV-C are independent isolates of the same virus.
admission and from some of the patients during follow-up. Serum
Together with HCV, HGV/GBV-C may belong to a distinct samples for PCR were aliquoted and stored at 070ЊC until analysis.
group of hepatitis viruses within the Flaviviridae family [14 -
The definition of maximum possible incubation period of the 16]. HGV RNA was detected in 1% -2% of blood donors in disease was the period from the first day of parenteral manipulation the United States [16] and is prevalent in patients with frequent (within 12 months before onset) to onset of disease (appearance parenteral exposure (intravenous drug users, hemodialysis paof dark urine or symptoms). The minimum possible incubation tients, and hemophiliacs) [17, 18] .
period was defined as the period from the last day of known HGV can also be detected in some patients with acute nonparenteral exposure to the first appearance of hepatitis symptoms.
A-E hepatitis, hepatitis C, and biopsy-documented chronic hepaThe mean incubation period was calculated from the minimum titis in which hepatitis B virus (HBV) and HCV were excluded and maximum incubation periods. The duration of the acute period of disease was defined as the period from onset to clear recovery, disappearance of jaundice and clinical symptoms, and significant decrease (to within 3 times normal) in concentrations of liver [20] . HCV antibodies were detected by using a second-generation EIA (Abbott) and further characterized with (35 cycles) in combination with the antisense primer YK 876 (5-CCTTACAGTCCTTATTGCTTCCTC-3). Each PCR cycle a supplemental immunoblot system (MATRIX HCV; Abbott).
Biochemical tests. Serum samples were assayed weekly during included denaturation at 94ЊC for 30 s, annealing at 60ЊC for 20 s, and extension at 72ЊC for 60 s. Five microliters of amplified the acute period of the disease for bilirubin, ALT, AST, g glutamyl aminotransferase, prothrombin time, protein, and protein fractions.
nested PCR solution was analyzed by electrophoresis in a 2% agarose gel containing 0.5 ng of ethidium bromide/mL. HCV RNA detection. HCV RNA was extracted from 100 mL of serum by the acid guanidine-phenol-chloroform method [21] , HGV RNA titration. HGV RNA-positive sera were serially diluted 10-fold in normal human serum followed by total RNA reverse-transcribed, and amplified by use of the biotinylated primer pairs KY 78 (5-biotin-CTCCAAGCACCCTATCAGGCAGT-3) extraction and HGV RNA detection by RT-PCR as described above. HGV RNA values were expressed as titer per milliliter of and KY 80 (5-biotin-GCAGAAAGCGTCTAGCCATGGCGT-3) derived from the HCV 5-untranslated region. The reverse transerum. Sequencing analysis. DNA was sequenced by use of PCR scription (RT)-PCR was performed according to previously described methods [22] with minor modifications by use of a thermal products from HGV RNA-positive patients for confirmation of specificity. The HGV RNA amplification product was purified cycler (9600; Perkin-Elmer Cetus, Norwalk, CT). The amplification product was detected by a colorimetric microwell assay by (QIAQuick Purification Kit; Qiagen, Chatsworth, CA) and sequenced in both directions with the HGV internal primers. The use of an HCV-specific solid-phase capture probe. The denatured PCR product was hybridized to the immobilized capture probe nucleotide sequence was determined with an automated DNA sequencer (ABI Prism 377; Perkin-Elmer Cetus). The consensus KY150 (5-GTTGGGTCGCGAAAGGCCTTGTGGT-3) in a microtiter plate (Immulon-2). The hybridized PCR product was desequence was aligned by use of the NALIGN module in the PCGENE 6.85 software package (Intelligenetics, Palo Alto, CA) tected by use of avidin-horseradish peroxidase conjugate and triethylbenzedine as substrate; absorbance was read at 450 nm.
with the GenBank wild type HGV sequence. Statistical analyses. Statistical analyses were performed by use Normal human and HCV antibody-positive sera were used as negative and positive controls, respectively. of the Pearson x 2 test, the Mantel-Haenszel x 2 test, and x 2 for trends, as appropriate. Statistical significance was determined by GBV-C RNA detection. GBV-C RNA was reverse-transcribed and amplified by use of primers (G9, G8, G11) from the published calculation with the Yates's correction factor and exact 95% confidence intervals. Data were analyzed by use of the Epi Info com-NS3 helicase region [14] as previously described [23] . Briefly, 4 mL of total RNA was reverse-transcribed by use of the antisense puter program, version 6 [24] . primer G9 (5-TCYTTGATGATDGAACTGTC-3; Y Å T or C; D Å A, G, or T) in 20 mL of RT master mix (as described for HCV RT master mix) at 37ЊC for 60 min, and the resulting cDNA A -E hepatitis patients, in contrast to 41% (9/22) of the acute in a final volume of 50 mL. The antisense primer G11
HCV-infected patients (P õ .003). Sequence analysis of both (including those with mixed HGV-HCV infections) were coma random hexamer primer. The PCR methodology was the same parable with those from HCV and non-A, non-G hepatitis paas that used for the G8-G11 primers, as described above.
tients. Seventy to eighty-five percent of the patients in each
HGV RNA detection. HGV RNA was detected by RT-nested PCR with primers from the NS-5 region of HGV. Reverse trangroup were exposed parenterally within 12 months before dis-/ 9d2a$$ju33 04-25-97 11:24:27 jinfa UC: J Infect gation, are necessary to establish the HGV transmission risk factors with greater certainty. All HGV RNA -positive patients were positive with at least ease onset (table 2) . Most patients presented with asthenovegeone set of GBV-C primers derived from the NS-3 region of tative symptoms, although some patients in each group exhibited dyspeptic symptoms. Flu-like symptoms (fever) were Table 2 . Clinical characteristics of patients with acute hepatitis acobserved in 8% (1/12) of the HCV patients and 29% (6/21) of cording to diagnostic group. the non-A, non-G hepatitis patients (P ú .2). Arthralgia was not present in any of the patients examined in this study. Com- GBV-C, confirming the close relationship of HGV and GBV-C.
cal symptoms and decrease in ALT concentrations) was the same for HCV and HGV patients. In contrast, patients with The use of a more highly conserved region of the GBV-C genome for PCR might increase the sensitivity of GBV-C RNA acute non-A, non-G hepatitis developed a moderately severe disease more frequently (79%), the mean duration of the disdetection in HGV RNA -positive samples.
Clinical and biochemical data were similar for the HCV-and ease was longer (19 { 9 days), and peak ALT concentrations were higher than in patients with either HGV or HCV infec-HGV-positive patients; all patients developed acute hepatitis without complications. None of the HGV/GBV-C -positive pations, suggesting that mixed HCV-HGV infection does not influence the severity of the disease. Prospective follow-up tients in this study developed severe forms of hepatitis; we did not find evidence that GBV-C plays an important role in studies of 4 HGV-positive patients showed that these patients had persistent viremia (9 -19 months), although none demonfulminant and subfulminant non-A -E hepatitis.
The mean period of acute infection (from beginning of strated symptoms of chronic liver disease and none had elevated serum aminotransferases during follow up. Long-term disease onset to the disappearance of jaundice and other clini- persistence of high-titer (10 4 -10 6 ) viremia after clinical and and histologic examination of biopsy material are necessary to conclusively establish if prolonged HGV viremia is more biochemical recovery and the absence of reduction of HGV RNA titers during convalescence suggest that these patients likely to lead to chronic hepatitis. The mechanism by which HGV infection persists remains might be chronic HGV carriers and that the acute hepatitis might be unrelated to HGV infection. An indirect indication of unknown. The frequency of development of chronic hepatitis and which form(s) of chronic hepatitis is likely to develop after a leading role for HCV in the pathogenesis of acute hepatitis in cases of mixed HGV-HCV infection was the disappearance acute infection also remain unclear. Despite a growing list of known viral hepatitis agents, the agent(s) of acute non-A -E of HCV RNA during follow-up in patients positive for both HGV and HCV RNA. Prospective studies of longer duration hepatitis remains to be elucidated. / 9d2a$$ju33 04-25-97 11:24:27 jinfa UC: J Infect
